About My Health Careers Internship MedBlogs Contact us
Medindia
LOGIN REGISTER
Advertisement

New Colorectal Cancer Vaccine Shows Positive Results in Phase 1 Trial

by Ramya Rachamanti on April 26, 2019 at 10:36 AM
Font : A-A+

New Colorectal Cancer Vaccine Shows Positive Results in Phase 1 Trial

Novel vaccine for colorectal cancer showed positive phase 1 clinical trial results. The vaccine is found to be safe and patients had no signs of dangerous side effects. Patient's blood samples were having markers of immune activation, indicating that the vaccine activated immune cells to fight colorectal tumors and metastases.

Further tests to determine if the vaccine is effective at slowing tumor growth are forthcoming. The results were published in the Journal for ImmunoTherapy of Cancer.

Advertisement


Colon cancer, especially in younger people, is on the rise and is currently the second highest cause of cancer deaths in the US and worldwide. Surgery can cure the disease in many patients, but prognosis is poor for those with recurrence of their disease. If it proves effective in larger-scale trials the vaccine, developed by researchers at Jefferson (Philadelphia University + Thomas Jefferson University), could train the patient's immune system to attack the colon cancer that had already spread before the surgery.

"There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient's own immune system to seek and destroy this cancer type. This is a true milestone-- made possible through the scientists and clinicians in our colorectal cancer team working in synchrony", said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center -- Jefferson Health.
Advertisement

In earlier preclinical work in mice, Jefferson researchers demonstrated how the design of their vaccine worked. Tumor vaccines have historically been developed against a sort of molecular sign-post for cancer. Because they come from normal cells, cancer cells share nearly all of the same molecules, making it difficult for the immune system to differentiate normal from cancerous. Tumor antigens are molecules that the immune system can recognize as different from normal. In colorectal cancer, one such molecule called GUCY2C, was identified by Scott Waldman, MD, PhD, the Samuel M.V. Hamilton Professor and Director of the Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center -- Jefferson Health.

The vaccine developed by first author, Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics, Dr. Waldman and others, works by activating the immune system against the GUCY2C molecule. By joining the GUCY2C molecule with a molecule that boosts the immune reaction called PADRE, and loading it into an adenovirus vector, the researchers engineered a vaccine that could specifically target the colon cancer.

The current clinical trial enrolled 10 patients with stage I or II colon cancer. Patients were given one dose and came back for blood draws 30, 90, 180 days after immunization. Patients experienced some discomfort at the injection site, but reported no serious side effects of the vaccine. The blood samples showed activation of "killer T cells," the immune cell type the researchers had expected. These killer T cells are responsible for finding and killing colon cancer cells that are responsible for causing the cancer to come back.

"We are preparing for a phase II study that will begin recruiting patients this fall," says Dr. Snook. "We used lessons learned in the first study to modify the vaccine to hopefully make it even more effective."

Since starting the trial, the researchers found that cancers other than colorectal cancer also express GUCY2C, including gastric, esophageal and pancreatic cancer. These are actually among the deadliest cancers. In fact, together with colorectal cancer, these four cancer types account for 20 percent of all cancer-related deaths.

"The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population," says Dr. Snook.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Emotional Healing
Psychosis Risk Related to Cat Parasite
Sedentary Behavior Precipitates Night-Time Hot Flashes
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Colo-rectal cancer - Management Colorectal Cancer Cancer Facts Cancer Tattoos A Body Art Colon Polyps Colorectal Cancer Screening Colorectal Cancer Screening with Colonoscopy Colorectal Cancer Screening with Double-Contrast Barium Enema 

Recommended Reading
Vaccine That Attacks Breast Cancer in Mice Developed
An effective vaccine that attacks tumors in mice has been developed by scientists in the United ......
Colo-rectal cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological t...
Colon Polyps
A colon polyp is a fleshy growth on the inside of the colon, also called the large intestine. In gen...
Colorectal Cancer
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancer is the third...
Colorectal Cancer Screening
Colorectal screening is done using tests to detect blood in stool, colonoscopy or sigmoidoscopy ordo...
Colorectal Cancer Screening with Colonoscopy
Colonoscopy is a widely used endoscopic procedure to screen individuals for colorectal cancer. It is...
Colorectal Cancer Screening with Double-Contrast Barium Enema
Double-contrast barium enema is a radiological technique that can be used to screen individuals for ...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use